Search alternatives:
decrease therapeutic » increased therapeutic (Expand Search), degrader therapeutics (Expand Search), great therapeutic (Expand Search)
therapeutic options » therapeutic applications (Expand Search)
host resistance » plant resistance (Expand Search)
decrease host » decreases short (Expand Search)
Showing 501 - 510 results of 510 for search '(( decrease host resistance ) OR ( decrease therapeutic options ))', query time: 0.31s Refine Results
  1. 501
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  2. 502
    Data Sheet 1_Naringenin attenuates slow-transit constipation by regulating the AMPK/mTOR/ULK1 signalling pathway: in vivo and in vitro studies.zip

    Data Sheet 1_Naringenin attenuates slow-transit constipation by regulating the AMPK/mTOR/ULK1 signalling pathway: in vivo and in vitro studies.zip by Yahui Wang (1305345)

    Published 2025
    “…</p>Conclusion<p>NAR attenuates the AMPK/mTOR/ULK1 pathway in ICCs, thereby improving STC colonic dysmotility and underscoring its promise as a therapeutic option for STC.</p>…”
    Save to List
    Saved in:
  3. 503
    Table 2_Determining the efficacy and safety of acupuncture for the treatment of menstrual migraine: an updated systematic review and meta-analysis.docx

    Table 2_Determining the efficacy and safety of acupuncture for the treatment of menstrual migraine: an updated systematic review and meta-analysis.docx by Qiqi Wu (4895728)

    Published 2025
    “…While acupuncture shows potential as a therapeutic option for MM, the existing evidence does not clearly support its routine clinical use. …”
    Save to List
    Saved in:
  4. 504
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  5. 505
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  6. 506
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  7. 507
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  8. 508
    Data Sheet 1_Modeling lymphocyte subset dynamics after ublituximab therapy in patients with multiple sclerosis: an Italian prospective study.pdf

    Data Sheet 1_Modeling lymphocyte subset dynamics after ublituximab therapy in patients with multiple sclerosis: an Italian prospective study.pdf by Aurora Zanghì (9202094)

    Published 2025
    “…This signature extends to older and high BMI patients, supporting ublituximab as a versatile therapeutic option across heterogeneous MS populations.…”
    Save to List
    Saved in:
  9. 509
    Figure 1; Figure 2; Figure 3; Figure 4; Figure 5; Table 1; Table 2; Table 3; Table 4; SupTable 1; SupTable 2; SupTable 3

    Figure 1; Figure 2; Figure 3; Figure 4; Figure 5; Table 1; Table 2; Table 3; Table 4; SupTable 1; SupTable 2; SupTable 3 by Ramachandran Chelliah (3837415)

    Published 2025
    “…This process is tightly regulated by host and environmental factors, including the gut microbiota. …”
    Save to List
    Saved in:
  10. 510
    Data Sheet 1_α-Mangostin prevents diabetic cardiomyopathy by inhibiting oxidative damage and lipotoxicity through the AKT–FOXO1–CD36 pathway.pdf

    Data Sheet 1_α-Mangostin prevents diabetic cardiomyopathy by inhibiting oxidative damage and lipotoxicity through the AKT–FOXO1–CD36 pathway.pdf by Xue Bai (129175)

    Published 2025
    “…These results suggest that A-MG may be a novel therapeutic option for DCM.</p>…”
    Save to List
    Saved in:

Search Tools: